Table 4.
Multivariate analysis of the inflammation-based cumulative prognostic score (ICPS) and IPI risk factors
| Characteristic | OS | PFS | ||
|---|---|---|---|---|
| P-value | HR (95% Cl) | P-value | HR (95% Cl) | |
| Age(>60y) | <0.001 | 2.493 (1.657–3.749) | 0.250 | 1.228(0.865–1.745) |
| Ann Arbor stage(III,IV) | 0.533 | 1.185(0.695–2.022) | 0.295 | 1.254(0.821–1.914) |
| LDH(>245 U/L) | 0.042 | 1.690(1.020–2.800) | 0.018 | 1.642(1.087–2.479) |
| ECOG PS(≥2) | 0.411 | 1.230(0.751–2.012) | 0.022 | 1.579(1.069–2.330) |
| Extranodal sites(>1) | 0.013 | 1.803(1.134–2.868) | 0.187 | 1.305(0.879–1.937) |
| ICPS ≥ 2 | 0.001 | 2.476 (1.483–4.136) | 0.019 | 1.611(1.080–2.404) |
Abbreviations: OS Overall survival, PFS Progression-free survival, HR Hazard Ratio, 95% Cl, 95% confidence limits, LDH Lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, IPI International Prognostic Index, Hi High-intermediate, H High, ICPS Inflammation-based cumulative prognostic score